

PHARMACEUTICAL COMPOUNDS FOR THE INHIBITION
OF HEPATITIS C VIRUS NS3 PROTEASE

Technical Field

5 This invention relates to compounds which can act as inhibitors of the hepatitis C virus (HCV) NS3 protease, to uses of such compounds and to their preparation.

Background Art

10 The hepatitis C virus (HCV) is the major causative agent of parenterally-transmitted and sporadic non-A, non-B hepatitis (NANB-H). Some 1% of the human population of the planet is believed to be affected. Infection by the virus can result in chronic hepatitis
15 and cirrhosis of the liver, and may lead to hepatocellular carcinoma. Currently no vaccine nor established therapy exists, although partial success has been achieved in a minority of cases by treatment with recombinant interferon- α , either alone or in combination
20 with ribavirin. There is therefore a pressing need for new and broadly-effective therapeutics.

 Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease
25 (NS2-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B). The NS3 protease

is located in the N-terminal domain of the NS3 protein,
and is considered a prime drug target since it is
responsible for an intramolecular cleavage at the NS3/4A
site and for downstream intermolecular processing at the
5 NS4A/4B, NS4B/5A and NS5A/5B junctions.

Previous research has identified classes of
peptides, in particular hexapeptides, showing degrees of
activity in inhibiting the NS3 protease. The aim of the
10 present invention is to provide further compounds which
exhibit similar, and if possible improved, activity.

According to the nomenclature of Schechter & Berger
(1967, Biochem. Biophys. Res. Commun. 27, 157-162)
15 cleavage sites in substrates for the NS3 protease are
designated P6-P5-P4-P3-P2-P1...P1'-P2'-P3'-P4'-, with each P
representing an amino acid, and the scissile bond lying
between P1 and P1'. Corresponding binding sites on the
enzyme are indicated as S6-S5-S4-S3-S2-S1...S1'-S2'-S3'-S4'.

20

The present applicant has previously disclosed so
called product inhibitors which are based on the P-region
of the natural cleavage sites and which have been
optimised to low nanomolar potency ((1998) Biochemistry
25 37: 8899-8905 and (1998) Biochemistry 37: 8906-8914).
These inhibitors extract much of their binding energy

WO 00/31129

PCT/EP99/09207

from the C-terminal carboxylate, the remaining
interactions with NS3 being similar to the ones used by
the natural substrates, including binding in the S₁ pocket
and the prominent electrostatic interaction of the P6-P5
5 acidic couple.

At variance with the P region, the P' region of
the substrate, while being important for catalysis, does
not influence significantly ground-state binding to the
10 enzyme as expressed by the K_m value. In other words,
binding energy released by the substrate interaction with
the enzyme to form an initial non-covalent complex is
essentially due to the interaction of the residues of the
P region; the P' region residues contribute to a lesser
15 extent to the binding energy. Accordingly, peptides
based on the P' region of the natural substrates (spanning
residues P₁'-P₁₀') do not inhibit NS3 to any significant
extent. This notwithstanding, inspection of the crystal
structure of NS3 with or without 4A (and more recently of
20 the NMR structure of NS3) shows the presence of binding
pockets in the S' region which might be exploited for the
binding of active-site directed inhibitors. S'-binding
ligands would therefore display a range of interactions
with the enzyme different from the ones used by the
25 substrate, and represent a novel class of NS3 inhibitors.

Landro et al in (1997) Biochemistry 36, 9340-9348 synthesized certain non-cleavable decapeptides based on the NS5A/5B cleavage site by substituting the P₁' serine by a bulky cyclic aromatic (tetrahydroisoquinoline-3-carboxylic acid) or smaller cyclic alkyl compound (proline or pipecolinic acid). They then investigated the interaction of these decapeptides with the substrate binding site of NS3 either in the presence or absence of NS4A cofactor. By looking at the effect of truncation at either the P or P' side of the molecule they concluded that most of the binding energy of the decapeptide is due to interactions with NS3-NS4A complex on the P side of the molecule. Truncation on the P' side produced a relatively large effect in the presence of NS4A cofactor, but less when NS4A was absent. They concluded that the P4' substrate Tyr residue present in their molecules was in close proximity, or in direct contact with NS4A and that this residue contributes significantly to binding in the presence of NS4A.

The present inventors have developed inhibitors which are more powerful than those described by Landro et al because they have better binding on their P' side. In other words, the inhibitors take advantage of binding to the S' region in addition to binding to the S-region of NS3. By varying the P' amino acid residues, the present

WO 00/31129

PCT/EP99/09207

inventors have shown that the binding energy which may be extracted from S'-region binding is substantial, since inhibitors with optimised and non-optimised P'-regions differ in potency > 1000-fold. Since no activity was present in any of the peptides corresponding to the isolated P'-region, optimisation of an S'-binding fragment was pursued in the context of non-cleavable decapeptides spanning P₆-P₄'.

10 The inventors found that, by replacing Landro's P4' Tyr residue by leucine the effectiveness of the decapeptides as NS3 protease inhibitors could be enhanced. Although it had been previously shown that leucine in position P4' is better than tyrosine in a
15 decapeptide substrate cleavable by NS3 (Urbani et al (1997) J. Biol. Chem 272, 9204-9209), this is the first showing that the same applies to decapeptide inhibitors which are not cleaved under the influence of the enzyme. By optimising the P4' residue and then the P2'-P3' fragment
20 and using these together with an optimised P region the inventors have arrived at oligopeptides which show potency in the low nanomolar-subnanomolar range.


Disclosure of the Invention

25 According to a first aspect of the present invention there is provided a compound having the formula (I)

WO 00/31129

PCT/EP99/09207

(written from N-terminus to C-terminus):



5 wherein "Pep" is a peptide or peptide analogue
capable of binding to HCV NS3 protease; in particular, it
is capable of binding in the S-region of the protease;

10 A' is proline which is optionally substituted, for
instance with one to three substituent groups;

15 B' is an amino acid or amino acid analogue having a
non polar side chain. Preferably, the side chain is an
alkyl, aryl or aralkyl group containing 3 to 10,
particularly 4 to 8 carbon atoms;

20 C' is an amino acid or amino acid analogue having a
polar side group. Examples of polar side group may
contain between 2 and 10, preferably 2 to 6 carbon atoms;

25 D' is leucine, or less preferably another amino acid
with a non-polar aliphatic side chain, such as valine,
isoleucine, norleucine or methionine. Alternatively, it
is a short peptide or peptide analogue having one of
these amino acids, especially leucine at its N terminus.
The short peptide or peptide analogue may, for instance

WO 00/31129

PCT/EP99/09207

comprise 2 to 6, preferably 2 to 4 amino acids or amino acid analogues.

As used herein, the term "amino acid analogue"
5 includes organic compounds containing an amino and a carboxylic acid group, for instance arranged α - to each other, and which do not necessarily occur in nature.

The Pep-A bond of the compound of formula (I) is
10 substantially uncleavable by HCV NS3 protease. For instance, it is preferable that no cleavage be detectable using the assay described below under the heading "Substrate Assay".

15 Pharmaceutically acceptable salts of the compound of formula (I), as well as derivatives, such as esters are within the scope of the present invention.

Preferably, the compound of formula (I) is N-
20 terminally acylated, especially acetylated, although other derivatives of the N-terminus are also possible, for instance N-terminal sulphoxide, sulphonamide, urethane or urea derivatives.

25 Preferably, the compound of formula (I) is C-terminally amidated. However, the C-terminus may be an

WO 00/31129

PCT/EP99/09207

underivatised carboxylic acid group. Alternatively,
other C-terminal groups may be present.

Assuming no substitution of the proline residue at A'
5 is present, then a preferred C-terminal portion of the
compound of formula I is:

Pro-B'-C'-Leu

10 possibly with a short C terminal extension at Leu.

Preferred examples of the amino acid, or analogue, B'
for inclusion in compounds of the first aspect of the
invention, include:

15 β -cyclohexylalanine, phenylglycine,
homophenylalanine and norleucine; other possibilities,
though less preferred, are leucine, methionine,
norvaline, and β -cyclopropylalanine. Of all these,
20 cyclohexylalanine and phenyl glycine are most preferred.

Examples of the amino acid or analogue, C' include
aspartic acid, glutamic acid, γ -carboxyglutamic acid,
glutamine, asparagine, and hydroxyproline. Slightly less
25 preferred are N- β -Aloc-diaminobutyric acid,
thiazolylalanine, methionine sulfoxide, pyridylalanine

WO 00/31129

PCT/EP99/09207

and serine. Of all of these aspartic acid is most preferred.

The following combinations of amino acid residues at
 5 B' and C' are preferred, of which the combination of
 cyclohexylalanine and aspartic acid is especially
 preferred.

TABLE 1

B'	C'
Cha	Ser
Cha	Asp
Nle	Asp
Hof	Asp
Phg	Asp
Cha	Gln
Nle	Gln
Hof	Gln
Cha	Hyp
Nle	Hyp
Hof	Hyp
Nle	Ser

Notes: Cha = β -cyclohexylalanine.

Nle = norleucine.

25 Phg = phenylglycine.

Hof = homophenylalanine.

Hyp = hydroxyproline.

When the residue D' is leucine (or other amino acid)

WO 00/31129

PCT/EP99/09207

with a small peptide as C-terminal extension the peptide may be chosen by comparison with the corresponding P' portion of natural substrates.

5 The residues A', B', C' and D' may have D- or L- stereochemistry, although L-stereochemistry is, in general, preferred for each.

10 As regards the Pep part of the compound of formula (I) this is particularly preferably a peptide or peptide analogue capable of binding to HCV NS3 protease, even in the absence of the C-terminal residues A'-B'-C'-D', for instance when Pep carries just a carboxylic acid group at the C terminus. For example, when tested in the
15 inhibition assay described below the fragment Pep-OH preferably has an IC₅₀ below 100µM, e.g. below 20µM, particularly below 10µM and, optimally, of less than 1µM. Preferably, Pep is a hexa-, penta- or tetra peptide having formula II below:

20



 wherein: A is an amino acid or amino acid analogue having a relatively small (C₁-C₆) aliphatic side chain.
25 Possible choices for this group include cysteine, aminobutyric acid (Abu) (including di- and tri-fluoro

WO 00/31129

PCT/EP99/09207

Abu), norvaline, allylglycine and alanine, any of which may be N-methylated. Of these, cysteine and the fluorinated aminobutyric acids are preferred choices for A.

5

B is an amino acid or analogue having a non-polar or acidic side chain. Some amino acids having polar but uncharged side groups may also be suitable. Examples of suitable amino acids include glutamic and aspartic acid, glycine and methyl glycine, 2-amino butyric acid, alanine, isoleucine, valine, leucine, cysteine, naphthylalanine and β -cyclohexylalanine. Of these, cyclohexylalanine is particularly preferred.

10

15

C is an amino acid or amino acid analogue having a non-polar or acidic side chain. For instance, the examples of such amino acids given above for B apply also to C. In this case isoleucine and glutamic acid are particularly preferred.

20

D is usually an amino acid or amino acid analogue having a hydrophobic side group such as methionine, isoleucine, leucine, norleucine, valine, methyl valine, phenylglycine or, diphenylalanine. Among these leucine and, particularly, diphenylalanine are preferred. Some polar amino acids which include hydrophobic portions,

25

WO 00/31129

PCT/EP99/09207

such as tyrosine, thienylalanine, and chlorophenylalanine may be suitable.

E together with F may be absent, but if present is generally an amino acid or amino acid analogue having an acidic side chain. Preferred examples are glutamic and aspartic acid, with the former being preferred. E may, alternatively, be an amino acid or analogue having a non-polar, or polar but uncharged side chain. Of the non-polar amino acids, phenylalanine, diphenylalanine, isoleucine and valine are preferred, especially the D-enantiomers. Among the polar amino acids suitable examples are tyrosine and 4-nitrophenylalanine. Alternatively, where F is absent (see below), E may be a dicarboxylic acid containing up to 6 carbon atoms and lacking the amino group of acidic amino acids. Suitable examples are glutaric and succinic acid.

F may be absent (either by itself, or together with E), but when present is an amino acid or analogue having an acidic side chain. Aspartic acid is preferred, although glutamic acid is another possibility. Like E, F may also be a dicarboxylic acid containing up to 6 carbon atoms, and lacking the amino group of acidic amino acids. Examples are glutaric and succinic acid.

WO 00/31129

PCT/EP99/09207

Of residues E and F preferably at least E is present. Particularly preferably both are present.

5 The amino acids and analogues A-F may be either L- or D- enantiomers though L- is generally preferred for all residues. In some cases it may be beneficial for one or other of the residues to be D- while the rest are L-. In particular it may be advantageous for E to be D-glu.

10 Preferred examples of the peptide "Pep" are listed below in Tables 2 and 3 together with their IC₅₀ values when unextended at the C-terminus. Except for the compounds having a succinyl residue at the N-terminus, all compounds tested were N-acetylated at the N-terminus.

WO 00/31129

PCT/EP99/09207

TABLE 2

Exp No.	Sequence	IC ₅₀ (μM)
1	Asp Glu Met Glu Glu Cys	1.0
2	Asp Glu Met Glu Glu D-Cys	4.0
3	Asp Glu Met Glu Glu Abu	5.8
4	Met Glu Glu Cys	150.0
5	Glu Met Glu Glu Cys	21.0
6	Glu Asp Val Val Cys Cys	5.3
7	Glu Asp Val Val Abu Cys	2.8
8	Asp Glu Val Val Cys Cys	2.1
9	Glu Asp Val Val Gly Cys	20.0
10	Asp Glu Met Glu Glu Alg	12.0
11	Glu Asp Val Val MGly Cys	21.0
12	Glu Asp MVal Val Abu Cys	1.3
13	GluS Met Glu Glu Cys	1.3
14	AsGlu Met Glu Glu Cys	0.6
15	Asp Glu Met Glu Leu Cys	1.1
16	Asp Glu Met Glu Cha Cys	0.3
17	Asp Glu Met Glu Nap Cys	0.8
18	AspS Val Val Abu Cys	4.6
19	Asp Glu Met Glu Glu Cys(Me)	16.7
20	Asp Glu Val Glu Cha Cys	0.33

WO 00/31129

PCT/EP99/09207

5

10

15

21	Asp Glu Ile Glu Cha Cys	0.12
22	Asp Glu Tyr Glu Cha Cys	0.24
23	Asp Glu Phe Glu Cha Cys	0.42
24	Asp Glu Leu Glu Cha Cys	0.12
25	Asp Glu Cha Glu Cha Cys	0.14
26	Asp Glu Nle Glu Cha Cys	0.22
27	Asp Glu Tha Glu Cha Cys	0.87
28	Asp Glu FCI Glu Cha Cys	0.3
29	Asp Glu Phg Glu Cha Cys	0.12
30	Asp Glu Dif Glu Cha D-Cys	3.4
31	Glu Dif Glu Cha Cys	1.4
32	Dif Glu Cha Cys	30.0
33	Asp MGlu Leu Glu Cha Cys	1.0
34	Asp Glu Dif Glu Cha DHAla	7.1
35	Asp Glu Met Glu Glu Cpc	9.0
36	Glu Dif Ile Cha Cys	2.5
37	Dif Ile Cha Cys	100.0
38	Asp Glu Met Glu Glu CnAla	19.0
39	Asp Glu Leu Glu Cha Abu	1.6

WO 00/31129

PCT/EP99/09207

40	Asp Glu Leu Glu Cha Val	4.0
41	Asp Glu Leu Glu Cha Nva	1.3
42	Asp-Asp-Leu-Glu-Cha-Cys	0.290
43	Asp-Fno-Leu-Glu-Cha-Cys	0.240
44	Asp-Tyr-Leu-Glu-Cha-Cys	0.135
45	Asp- (D) Phe-Leu-Glu-Cha-Cys	0.820
46	Asp- (D) Tyr-Leu-Glu-Cha-Cys	0.680
47	Asp- (D) Val-Leu-Glu-Cha-Cys	0.470
48	Asp- (D) Ile-Leu-Glu-Cha-Cys	0.330
49	Asp- (D) Dif-Leu-Glu-Cha-Cys	0,276
50	Asp- (D) Asp-Leu-Glu-Cha-Cys	0,122
51	Asp-Glu-Dap (N-b-Dns) -Glu-Cha-Cys	0,4

5

10

Particularly preferred examples of Pep, together
with their IC₅₀s (in μ M) are set out below in Table 3 are:

TABLE 3

5

Most preferred:

10

15

20

1	Asp Glu Dif Glu Cha Cys	0.05
2	Asp Glu Leu Val Cha Cys	0.08
3	Asp Glu Leu Ile Cha Cys	0.06
4	Asp Glu Dif Ile Cha Cys	0.06
5	Asp-Gla-Leu-Glu-Cha-Cys	0.055
6	Asp- (D) Glu-Leu-Glu-Cha-Cys	0.045
7	Asp- (D) Gla-Leu-Ile-Cha-Cys	0.0015
8	Glu-Leu-Glu-Cha-Cys	1.3
9	(D) Glu-Leu-Glu-Cha-Cys- (Pro-Cha-Asp-Leu)	0.080*
10	Succinyl Glu-Leu-Ile-Cha-Cys	
11	Succinyl (D) Glu-Leu-Glu-Cha-Cys- (Pro-Cha- Asp-Leu)	0.0040*
12	Asp- (D) Glu-Leu-Ile-Cha-Cys	
13	Asp- (D) Glu-Leu-Ile-Cha-Cys- (Pro-Cha-Asp- Leu)	<0.0002*

* Tested only as decapeptides

WO 00/31129

PCT/EP99/09207

In these compounds:

	Alg	=	allylglycine.
5	MGly	=	methylglycine.
	MVal	=	methylvaline.
	Abu	=	2-aminobutyric acid.
	GluS	=	N-succinylglutamic acid.
10	AsGlu	=	Glutamic acid having N-terminal acylsulphonamide.
	Cha	=	β -cyclohexylalanine.
	Nap	=	naphthylalanine.
	AspS	=	N-succinylaspartic acid.
	Nle	=	norleucine.
15	Dif	=	3,3-diphenylalanine.
	Tha	=	2-thienylalanine.
	FCI	=	4-chlorophenylalanine.
	Phg	=	phenylglycine.
	CysMe	=	S-methylcysteine.

WO 00/31129

PCT/EP99/09207

	Cys (ACS)	=	Cysteine with C-terminal acylsulphonamide.
	DHAla	=	dehydroalanine.
5	Cpc	=	1-amino-1-cyclopentane carboxylic acid.
	CnAla	=	cyanoalanine.
	MGlu	=	N-methylglutamic acid.
	Fno	=	4-nitrophenylalanine.
	Gla	=	γ -carboxyglutamic acid.
10	Dap	=	β -diaminopropionic acid.
	Dns	=	dansyl (5-dimethylamino-1- naphthalene-sulfonyl).

Examples of compounds of the present invention may
15 be effective as inhibitors of NS3 protease at micromolar
or nanomolar levels. Preferably, the IC_{50} , as measured in
the assay described below is less than 100nM,
particularly preferably less than 20nM and, optimally,
less than 5nM.

WO 00/31129

PCT/EP99/09207

According to a second aspect, the present invention provides a compound, salt or derivative according to the first aspect, for use in any therapeutic method, preferably for use in inhibiting the HCV NS3 protease, and/or for use in treating or preventing hepatitis C or a related condition. By "related condition" is meant a condition which is or can be caused, directly or indirectly, by the hepatitis C virus, or with which the HCV is in any way associated.

10

According to a third aspect the present invention provides the use of a compound or derivative according to the first aspect in the manufacture of a medicament for the treatment or prevention of hepatitis C or a related condition.

15

A fourth aspect of the invention provides a pharmaceutical composition which includes one or more compounds or derivatives according to the first aspect.

WO 00/31129

PCT/EP99/09207

The composition may also include pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers and other excipients. It may additionally include other therapeutically active agents, in particular those of use in treating or preventing hepatitis C or related conditions.

The pharmaceutical composition may be in any suitable form, depending on the intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally.

According to a fifth aspect of the invention, there is provided a method of inhibiting HCV NS3 protease activity, and/or of treating or preventing hepatitis C or a related condition, the method involving administering to a human or animal (preferably mammalian) subject suffering from the condition a therapeutically or

WO 00/31129

PCT/EP99/09207

prophylactically effective amount of a composition according to the fourth aspect of the invention, or of a compound or derivative according to the first aspect.

"Effective amount" means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject's condition.

The dosage rate at which the compound, derivative or composition is administered will depend on the nature of the subject, the nature and severity of the condition, the administration method used, etc. Appropriate values can be selected by the trained medical practitioner. Preferred daily doses of the compounds are likely to be of the order of about 1 to 100 mg. The compound, derivative or composition may be administered alone or in combination with other treatments, either simultaneously or sequentially. It may be administered by any suitable route, including orally, intravenously, cutaneously, subcutaneously, etc. Intravenous administration is preferred. It may be administered directly to a suitable

WO 00/31129

PCT/EP99/09207

site or in a manner in which it targets a particular site, such as a certain type of cell - suitable targeting methods are already known.

5 A sixth aspect of the invention provides a method of preparation of a pharmaceutical composition, involving admixing one or more compounds or derivatives according to the first aspect of the invention with one or more pharmaceutically acceptable adjuvants, and/or with one or
10 more other therapeutically or prophylactically active agents.

 According to a seventh aspect of the invention there is provided a method of producing the compounds of
15 formula I. These compounds may be generated wholly or partly by chemical synthesis beginning from individual, preferably protected, amino acids or oligopeptides and using known peptide synthesis methods.

Modes for Carrying Out the Invention

Embodiments of the invention are exemplified below by way of illustration only.

5 EXAMPLES(1) Synthesis

The synthesis of one of the compounds of the present invention is described below. Other compounds may be
10 synthesized by an analogous method.

Synthesis of Ac-Asp-(D)Glu-Leu-Ile-Cha-Cys-Pro-Cha-
Asp-Leu-Pro-Tyr-Lys (N^ε-Ac) -NH₂

15 The synthesis was performed on solid phase by the continuous-flow Fmoc-polyamide method (Atherton, E. and Sheppard, R. C. (1989) Solid phase peptide synthesis. A practical approach, IRL Press, Oxford.). The resin used was Tentagel™ derivatised with a modified Rink amide

linker p-[(R,S)- α -[1-(9H-Fluoren-9-yl)-methoxyformamido]-
2,4-dimethoxybenzyl]-phenoxyacetic acid (Rink, H. (1987)
Tetrahedron Lett. 28, 3787-3789; Bernatowicz, M. S.,
Daniels, S. B. and Koster, H. (1989) *Tetrahedron Lett.*
5 30, 4645-4667). All the coupling reactions were performed
for 30 min with 5-fold excess of activated amino acid
over the resin free amino groups, using Fmoc-amino
acid/PyBOP/HOBt/DIEA (1:1:1:2) activation; double
coupling was used for the cysteine residue. At the end of
10 the assembly, the dry peptide-resin was treated with
trifluoroacetic acid/water/triisopropylsilane
(92.5:5:2.5) for 1.5h at room temperature; the resin was
filtered out and the peptide precipitated with cold
methyl t-Bu ether; the precipitate was redissolved in 50%
15 water/acetonitrile containing 0.1%TFA and lyophilised.

Purification to >98% homogeneity was achieved
through preparative HPLC on a Waters RCM (C-18) column
(100 X 25 mm, 15mm) using as eluents (A) 0.1%
20 trifluoroacetic acid in water and (B) 0.1%

WO 00/31129

PCT/EP99/09207

trifluoroacetic acid in acetonitrile. The gradient used was 40%B isocratic for 5 min, then 40-60%B over 20 min, flow rate 30 ml/min; the fractions were analysed by HPLC (column: Beckman Ultrasphere, C-18, 25 X 4.6 mm, 5mm; gradient: 35-65%B in 20 min, same eluents as the preparative run, flow 1ml/min) and those containing the pure material were pooled and lyophilised (yield=50%). The Mass spectrum was acquired on a Perkin-Elmer API-100 spectrometer: MS= 1695.03 (calc.) 1694.6 (found).

(2) Inhibition Assay

The ability of the compounds to inhibit NS3 protease was evaluated using an NS3/4A complex comprising the NS3 protease domain and a modified form of the NS4A peptide, Pep 4AK [KKKGSVVIVGRIILSGR(NH₂)]. As substrate, a substrate peptide 4AB [DEMEECASHLPYK] based on the sequence of the NS4A/NS4B cleavage site of the HCV polyprotein, was used.

Cleavage assays were performed in 57 μ l 50 mM Hepes pH7.5, 1 % CHAPS, 15 % glycerol, 10 mM DTT (buffer A), to which 3 μ l substrate peptide were added. As protease co-factor a peptide spanning the central hydrophobic core (residues 21-34) of the NS4A protein, Pep4AK [KKKGSVVIVGRIILSGR(NH₂)] was used. Buffer solutions containing 80 μ M Pep4AK were preincubated for 10 minutes with 10-200 nM protease and reactions were started by addition of substrate. Six duplicate data points at different substrate concentrations were used to calculate kinetic parameters. Incubation times were chosen in order to obtain <7% substrate conversion and reactions were stopped by addition of 40 μ l 1 % TFA. Cleavage of peptide substrates was determined by HPLC using a Merck-Hitachi chromatograph equipped with an autosampler. 80 μ l samples were injected on a Lichrospher C18 reversed phase cartridge column (4 x 74mm, 5 μ m, Merck) and fragments were separated using a 10-40 % acetonitrile gradient a 5%/min using a flow rate of 2.5ml/min. Peak detection was accomplished by monitoring both the

WO 00/31129

PCT/EP99/09207

absorbance at 220nm and tyrosine fluorescence ($\lambda_{ex} = 260$
nm, $\lambda_{em} = 305$ nm). Cleavage products were quantitated by
integration of chromatograms with respect to appropriate
standards. Kinetic parameters were calculated from
5 nonlinear least-squares fit of initial rates as a
function of substrate concentration with the help of a
Kaleidagraph software, assuming Michaelis-Menten
kinetics.

10 K_i values of peptide inhibitors were calculated from
substrate titration experiments performed in the presence
of increasing amounts of inhibitor. Experimental data
sets were simultaneously fitted to eq.1 using a
multicurve fit macro with the help of a Sigmaplot
15 software:

$$V = (V_{max}S) / (K_m(1+K_i/I)+S); \quad (eq.1)$$

Alternatively, K_i values were derived from IC50

values, calculated using a four-parameter logistic function, according to eq.2:

$$IC_{50} = (1+S/K_m)K_i \quad (eq.2)$$

5

The table below sets out the IC_{50} values for a variety of peptides tested in this assay and establishes that several optimised compounds of the present invention are active at nanomolar or subnanomolar levels. All the compounds tested - except for compound 26 which has a succinyl residue at the N-terminus- were tested as their N-acetyl derivatives.

Some of these compounds are the most potent in vitro inhibitors of HCV protease described to date. They are reversible, non covalent inhibitors which do not contain an electrophilic ("serine-trap") moiety in the molecule. They bind to both the S and S' region of the enzyme, and this makes them suitable for developing competition

WO 00/31129

PCT/EP99/09207

binding assays, since they would be competitive with compounds binding to either the S or the S' region of the enzyme.

Table 4

Ex. No	Sequence	IC ₅₀ (nM)
1	Glu Asp Val Val Abu Cys Pro Nle Ser Tyr	8500
2	Glu Asp Val Val Abu Cys (Me)Ala Nle Ser Tyr	3500
3	Asp Glu Dif Ile Cha Abu Ala Ser His Leu	29000
4	Asp Glu Dif Ile Cha Abu (Me)Ala Ser His Leu	29000
5	Asp Glu Dif Ile Cha (Me)Abu Ala Ser His Leu	8000
6	Asp Glu Dif Ile Cha (Me)Abu (Me)Ala Ser His Leu	3800
7	Asp (D)Glu Dif Ile Cha (Me)Abu (Me)Ala Ser His Leu	3100
8	Asp (D)Glu Leu Ile Cha Abu (Me)Ala Ser His Leu	5000
9	Asp Glu Dif Ile Cha Cys Pro Nle Ser Tyr	876
10	Glu Dif Ile Cha Cys Pro Nle Ser Leu	64
11	Asp Glu Dif Ile Cha Cys Pro Cha Ser Leu	23
12	Asp Glu Dif Ile Cha Cys Pro Cha Asp Leu	1.3
13	Asp Glu Dif Ile Cha Cys Pro Phg Asp Leu	7
14	Asp Glu Dif Ile Cha Cys Pro Nle Asp Leu	1.8
15	Asp Glu Dif Ile Cha Cys Pro Hof Asp Leu	1.8
16	Asp Glu Dif Ile Cha Cys Pro Cha Gln Leu	14
17	Asp Glu Dif Ile Cha Cys Pro Nle Gln Leu	32
18	Asp Glu Dif Ile Cha Cys Pro Hof Gln Leu	18

WO 00/31129

PCT/EP99/09207

19	Asp Glu Dif Ile Cha Cys Pro Cha Hyp Leu	11
20	Asp Glu Dif Ile Cha Cys Pro Nle Hyp Leu	26
21	Asp Glu Dif Ile Cha Cys Pro Hof Hyp Leu	15
22	Asp (D)Glu Leu Ile Cha Cys Pro Nle Ser Leu	10
23	Asp Glu Dif Ile Cha Cys Pro Cha Asp Leu PYK(Ac)	0.85
24	Asp (D)Glu Leu Ile Cha Cys Pro Cha Asp Leu PYK(Ac)	< 0.2
25	Asp (D)Glu Leu Ile Cha Cys Pro Cha Asp Leu	< 0.2
26	Suc-(D)Glu Leu Ile Cha Cys Pro Cha Asp Leu	4
27	Asp (D)Glu Leu Glu Cha Cys Pro Cha Asp Leu	0.63
28	(D)Glu Leu Glu Cha Cys Pro Cha Asp Leu	80
29	Asp (D)Glu Leu Glu Cha Ala Pro Cha Asp Leu	17
30	Asp (D)Glu Leu Ile Cha Cys Pro Nle Ser Leu	10

WO 00/31129

PCT/EP99/09207

Abbreviations used in Table I:

Abu = aminobutyric acid

Cha = β -cyclohexylalanine

Hof = homophenylalanine

5 Hyp = hydroxyproline

Lys(Ac) or K(Ac) = Ne-Acetyl-Lysine

Nle = norleucine

Phg = phenylglycine

Sta = statine [(3S,4S)-4-amino-3-hydroxy-6-
10 methylheptanoic acid]

Dif = 3,3-diphenylalanine

Suc=succinyl

N-methylation is indicated as (Me) preceding the three-
letter code of the amino acid

15 PYK = proline-tyrosine-lysine

(3) Substrate Assay

In order to determine whether or not an inhibitor
molecule was a substrate for HCV NS3 protease a modified

WO 00/31129

PCT/EP99/09207

version of the cleavage assay described above was employed using, as before, an NS3/4A complex comprising the NS3 protease domain and a modified form of the NS4A peptide, Pep4AK [KKKGSVVIVGRIILSGR(NH₂)].

5

1µM of the enzyme complex was incubated for 16hrs in the presence of 10µM inhibitor as a candidate substrate peptide. Assays were performed in 57µl 50 mM Hepes pH7.5, 1% CHAPS, 15% glycerol, 10 mM DTT.

10

After this time HPLC was used to separate any peptides resulting from cleavage and separated cleavage products detected.

15

Samples were analysed by HPLC on a Beckman 0.46 x 25 cm C18 reversed phase column equilibrated in 95% solvent A (0.1% TFA in H₂O) and 5% solvent B (0.1% TFA in acetonitrile) at a flow rate of 1 ml/min. Samples were eluted from this column with a linear gradient from 5% to

WO 00/31129

PCT/EP99/09207

90% of B in 45 minutes. Peak detection was accomplished
by monitoring absorbance at 220 nm.